SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DMB who wrote (1616)11/1/1998 11:58:00 PM
From: Webhead   of 1762
 
You're right; Rituxan could activate some pathway leading to programmed cell death (apotosis) or exert some toxic effect. But, a cell lysis assay could still be due to complement activation (where a huge cascade of reactions leads to holes getting punched out of the cell followed by cell lysis). I seem to recall an old lab where we lysed red blood cells using complement and an antibody. I guess that the bottom line is that we can speculate on endlessly but unless we hear something from IDEC we're just flapping our gums! I may check some of IDEC's patents because they might contain useful information regarding the mechanism of cell killing. By whatever means, Rituxan is still (I think) the only monoclonal antibody that, by itself, can kill tumor cells.
Ed
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News